Trial Profile
A Prospective, Multicentric, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog Glargine Plus Glulisine With Premixed Insulin in Adult Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Sep 2019
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Insulin glulisine (Primary) ; Insulin aspart/insulin protamine aspart
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 09 Sep 2019 Status changed from active, no longer recruiting to completed.
- 15 Mar 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Sep 2018.
- 15 Mar 2018 Status changed from recruiting to active, no longer recruiting.